Effect of intracoronary adenosine on ergonovine-induced vasoconstricted coronary arteries

Authors: Jun-Hyok Oh, Seunghwan Song, Changhoon Kim, Jinhee Ahn, Jin Sup Park, Hye Won Lee, Jung Hyun Choi, Han Cheol Lee, Kwang Soo Cha, Taek Jong Hong

DOI: 10.5603/CJ.a2018.0072

Article type: Original articles

Submitted: 2018-02-14

Accepted: 2018-06-30

Published online: 2018-07-13

This article has been peer reviewed and published immediately upon acceptance. It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited. Articles in "Cardiology Journal" are listed in PubMed.
Effect of intracoronary adenosine on ergonovine-induced vasoconstricted coronary arteries

Running Head: Adenosine effect on the vasoconstricted epicardial coronary artery

Jun-Hyok Oh1, Seunghwan Song2, Changhoon Kim3, Jinhee Ahn1, Jin Sup Park1, Hye Won Lee1, Jung Hyun Choi1, Han Cheol Lee1, Kwang Soo Cha1, Taek Jong Hong1

1Department of Cardiology, Medical Research Institute, Pusan National University Hospital, Busan, South Korea
2Department of Thoracic and Cardiovascular Surgery, Medical Research Institute, Pusan National University Hospital, Busan, South Korea
3Department of Preventive Medicine, Medical Research Institute, Pusan National University Hospital, Busan, South Korea

Address for correspondence: Dr. Taek Jong Hong, Department of Cardiology, Medical Research Institute, Pusan National University Hospital, 179 Gudeok-ro, Seo-gu, Busan, 49241, South Korea, tel: +82-51-240-7794, fax: +82-51-240-7796, e-mail: md-tjhong@hanmail.net

Abstract

Background: This study aimed to evaluate the effect of adenosine on epicardial coronary artery diameter during ergonovine provocation testing.

Methods: A total of 158 patients who underwent an ergonovine provocation test with intracoronary adenosine injection between 2011 and 2014 were selected. Patients were divided into four groups based on the severity of percent diameter stenosis following intracoronary ergonovine administration: Group 1, induced spasm < 50%; Group 2, 50–89%; Group 3, 90–99%; and Group 4, total occlusion.
**Results:** Spasm positivity was observed in 44 (27.8%) cases in the study population (mean age, 57.4 ± 10.7 years). Intracoronary adenosine increased the diameter of the ergonovine-induced epicardial artery by 0.51 ± 0.31 mm, 0.73 ± 0.39 mm, 0.44 ± 0.59 mm, and 0.01 ± 0.04 mm in Groups 1, 2, 3, and 4, respectively. Subsequent administration of nitroglycerin further increased vessel diameter by 0.49 ± 0.28 mm, 0.93 ± 0.68 mm, 2.11 ± 1.25 mm, and 2.23 ± 0.69 mm in Groups 1, 2, 3, and 4, respectively. The ratios of adenosine-induced diameter to reference diameter were significantly lower in patients with spasm positive results (0.68 [0.59–0.76] vs. 0.18 [0.00–0.41], p < 0.001 in the study population; 0.60 [0.54–0.67] vs. 0.40 [0.27–0.44], p < 0.001 in Group 2) with the best cut-off value of 0.505 (sensitivity 0.955, specificity 0.921).

**Conclusions:** Intracoronary administration of adenosine dilated the ergonovine-induced vasoconstricted epicardial coronary artery. The ratio of adenosine-induced diameter to reference diameter was significantly lower in patients with spasm positive results.

**Key words:** ergonovine, adenosine, vasospasm, coronary artery, angina

**Introduction**

Coronary artery spasm has been recognized as the main pathomechanism for variant angina, as well as acute myocardial infarction and sudden cardiac death in severe cases [1–4]. It has been shown to be correlated with early atherosclerosis and has a higher prevalence in Asian populations than Caucasians [5, 6]. Ergonovine maleate is a weak vasoconstrictor, and induces a vasoconstrictor response in susceptible epicardial coronary arteries. This response is mediated by endothelium-independent smooth muscle hyperconstriction and more pronounced with endothelial dysfunction [7, 8]. In patients with confirmed variant angina, ergonovine provocation can induce coronary artery spasm at the same site where spontaneous spasm was observed with high diagnostic sensitivity and specificity [9, 10]. Adenosine is an endogenous neurotransmitter that can be synthesized by de novo purine biosynthesis or produced by degradation of 5'-adenosine triphosphate and 5'-adenosine monophosphate [11, 12]. Its biologic effects include inhibition of platelet aggregation, modulation of the inflammatory response, negative chronotropic and dromotropic effects, and induction of coronary vasodilation, predominantly affecting microvessels < 150 μm in diameter [13]. Due to its potent vasodilator effect in coronary microvessels, it has been the most widely used
drug to achieve hyperemia while measuring fractional flow reserve (FFR) in the coronary artery bed. However, the effect of adenosine on the ergonovine-induced vasoconstricted epicardial coronary artery has not been elucidated. The purpose of this study was to investigate the response of ergonovine-induced vasoconstricted epicardial coronary artery to adenosine and to clarify the suitability of FFR measurement using intracoronary adenosine on that vasoconstricted epicardial coronary artery.

**Methods**

**Study population**

From June 2011 to June 2014, the spasm provocation test with selective intracoronary injection of ergonovine was performed in 464 patients deemed to have variant angina. When a spasm was induced, adenosine administration into the spasm-induced coronary artery has been recommended routinely since 2011. A total of 158 patients who received intracoronary adenosine during the provocation test were identified and analyzed retrospectively. Informed consent for the test using both ergonovine and adenosine was obtained from each patient, and the study was approved by the Institutional Review Board of the hospital.

**Ergonovine provocation test**

The left coronary artery (LCA) and the right coronary artery (RCA) were provoked to spasm according to a standard manner recommended by the Japanese Circulation Society [14, 15]. Calcium antagonists, long-acting nitrates, and nicorandil were discontinued at least 48 h before the provocation test, except for as needed sublingual nitroglycerin.

Baseline coronary angiography was obtained with a 5-French (Fr) catheter via the femoral or radial artery (57 cases), which have been the default access points since 2012. The provocation test was performed when there was no significant stenosis (> 75% luminal narrowing). Stepwise doses of methylergometrine maleate (ER) (Daewon Pharm, Seoul, Korea) were selectively administered into the LCA (10, 20, and 20 μg) and RCA (10, 10, and 20 μg) with 3-min intervals between each dose. RCA spasm provocation was initiated after a
5-min washout period following LCA provocation. Coronary angiograms were obtained with each ER administration or when chest pain and/or ST-segment changes occurred. A selective dose of adenosine, 60 μg for the LCA and 40 μg for the RCA corresponding to the standard dose for FFR measurement, was injected into the coronary artery which had the maximum induced spasm and was followed by repeated coronary angiogram [16]. Intracoronary nitroglycerin was then administered until the spasm was entirely relieved and final coronary angiogram was performed.

A positive response was defined as transient greater than 90% diameter stenosis on coronary angiography, regardless of symptoms or sign of ischemia, or greater than 70% diameter stenosis with ischemic electrocardiography (ECG) changes and/or chest pain.

**Quantitative angiographic analysis**

End-diastolic cineframes in the same projection were selected and analyzed separately by two independent investigators using QCA software (Xcelera, Philips Medical Systems, the Netherlands). The coronary artery luminal diameter was measured in millimeters using a contrast-filled catheter as the calibration source. The most severely narrowed segment was termed the spasm segment and its diameter in response to ER, adenosine, and nitroglycerin were termed Diameter\(_{\text{ER}}\), Diameter\(_{\text{Ade}}\), and Diameter\(_{\text{Nit}}\), respectively. When control angiograms of the LCA were obtained after a full-dose provocation of the RCA, the diameter was noted as Diameter\(_{\text{control}}\). Reference diameter (Diameter\(_{\text{Ref}}\)) was defined as the average of the diameter of the nearest normal-looking segments before and after the spasm segment. The degree of induced spasm was calculated as \([1 – (\text{Diameter}_{\text{ER}} / \text{Diameter}_{\text{Ref}})] \times 100\) and noted as %Spasm. The differences in diameter between Diameter\(_{\text{ER}}\) and Diameter\(_{\text{Ade}}\), and between Diameter\(_{\text{Nit}}\) and Diameter\(_{\text{Ade}}\) were noted as ∆Adenosine and ∆Nitroglycerin, respectively. The sum of the change in diameter between Diameter\(_{\text{ER}}\) and Diameter\(_{\text{Nit}}\) was calculated as ∆Sum = Diameter\(_{\text{Nit}}\) – Diameter\(_{\text{ER}}\).

**Statistical analysis**

For the purpose of this study, patients were categorized into four groups according to the %Spasm as follows: Group 1, 0–50%; Group 2, 50–90%; Group 3, 90–99%; Group 4,
total occlusion. The normality of continuous data was tested using the Kolmogorov-Smirnov test. Skewed variables were analyzed after logarithmic or power transformation, accordingly. Continuous variables are expressed as the mean ± standard deviation (SD) or median (interquartile range) and assessed with the Student t-test or Mann-Whitney U test. Within-group comparisons were performed with repeated measures analysis of variance (ANOVA) with post hoc analysis using Bonferroni corrections. Comparison of the mean values among groups was made using one-way ANOVA. Trends were assessed using the linear-by-linear association χ² test or the linear term in ANOVA. Categorical variables are presented as frequencies and compared using the Fisher exact probability test. The receiver-operating curve was created to draw the best cut-off value of the ratio of Diameter_{Ade} / Diameter_{Ref} and discriminate the result of the spasm test. Correlations between variables were tested using linear regression analysis. Multivariate linear regression analysis was applied to identify the predictors for the Diameter_{Ade} / Diameter_{Ref} ratio. Statistical significance was defined as p < 0.05. All statistical calculations were performed using the SPSS software version 17.0 (IBM SPSS Inc., Chicago, IL).

**Results**

**Clinical characteristics**

A total of 158 patients were included in the study and categorized into the following four groups: Group 1, 50 (32.9%) patients; Group 2, 82 (51.9%) patients; Group 3, 9 (5.7%) patients; and Group 4, 15 (9.5%) patients. Mean ages ranged from 57.4 ± 10.7 years without significant differences among groups (Table 1). There was a tendency for increasing male population (p < 0.001) and current smoking (p = 0.037) from Groups 1–4. No significant difference was seen in the incidence of diabetes mellitus, hypertension, hyperlipidemia and clinical presentations between groups.

Methylerogometrine maleate provocation test was performed via the radial artery in 57 (36.1%) and femoral artery in 101 (63.9%) patients (Table 2). Overall, 44 (27.8%) patients had a positive response. There were no provocation-related adverse events including death, myocardial infarction, stroke, or bleeding that required a procedure or transfusion. There was 1 case of contrast allergy, and 3 cases of self-limiting and transient bradycardia in response to adenosine.
Changes in vessel diameter

The investigated vessels were the left anterior descending artery (LAD) and its branches in 60 (38.0%) patients, left circumflex artery (LCX) and its branches in 12 (7.6%), RCA and its branches in 82 (51.9%), and left main in 4 (2.5%) patients. Two representative cases are depicted in Figure 1. The cumulative dose of injected ER was significantly lower in Group 3 and 4, compared with the other groups. Although Diameter_{Ref} was similar between groups, Diameter_{ER}, Diameter_{Ade}, and Diameter_{Nit} progressively decreased from Group 1 to Group 4.

Adenosine was administered into the same coronary artery immediately after the angiogram of the last dose of ER in 114 cases (32 LCA, 82 RCA). In the remaining 44 cases, adenosine was injected into the LCA after a full provocation of the RCA, where control angiograms of the LCA revealed an increase in diameter of the vessel (Diameter_{ER}, 1.65 ± 0.75 mm; Diameter_{Control}, 1.90 ± 0.75 mm). Adenosine further dilated the vessel (Diameter_{Ade}, 2.31 ± 0.76 mm), but lesser than Diameter_{Nit} (2.82 ± 0.82 mm) in those patients. Overall, the increase in diameter with adenosine (ΔAdenosine) progressively decreased from Group 1 to Group 4, but the amount by nitroglycerin (ΔNitroglycerin) did vice versa. Adenosine did not increase the vessel diameter in Group 4 (Diameter_{ER}, 0.00 ± 0.00; Diameter_{Ade}, 0.01 ± 0.04, paired t-test \(p = 0.334\)).

Adenosine response based on test results

All patients in Group 3 and 4 had spasm positive results using the angiographic definition, while 20 (24.5%) had spasm positive results in Group 2. There was a significant increase in diameter following adenosine and nitroglycerine injection regardless of the result of the spasm test. Overall, there was a significant interaction between the pattern of diameter increase and the test result (\(n = 158; F[1.597, 249.1] = 77.271; p < 0.001\)) (Fig. 2A). There was a greater increase in diameter following adenosine injection (ΔAdenosine) in those with spasm negative results, than in those with spasm positive results (0.64 ± 0.36 vs. 0.41 ± 0.50, \(p = 0.002\)). The increase in diameter following nitroglycerine (ΔNitroglycerin) was significantly greater in those with spasm positive results than those with spasm negative
results (1.84 ± 0.98 vs. 0.64 ± 0.44, p < 0.001). There was also a significant interaction between diameter changes and the test results in Group 2 (F [1.567, 125.323] = 11.877, p < 0.001) (Fig. 2B). The ΔAdenosine of those with spasm negative results and with spasm positive results were similar (0.75 ± 0.37 vs. 0.70 ± 0.46, p = 0.648). However, the ΔNitroglycerin was significantly greater in those with spasm positive results than in those with spasm negative results (0.77 ± 0.51 vs. 1.41 ± 0.89, p < 0.001).

Ratio of Diameter_{Ade} to Diameter_{Ref}

Compared with the reference vessel diameter or the ratio of Diameter_{Ade} to Diameter_{Ref}, vessel diameter after adenosine injection was significantly smaller in patients with spasm positive results than in those with negative results in the overall study population (median, 0.18 vs. 0.68, p < 0.001) (Fig. 3A). A similar trend was seen for the ratio in Group 2 (median, 0.40 vs. 0.60, p < 0.001) (Fig. 3B). The best cut-off value for the prediction of a spasm positive result was 0.505, with a sensitivity of 96% and specificity of 92% (Fig. 4). Multivariate linear regression analysis found that current smoking (odds ratio [OR] 0.219; confidence interval [CI] 0.047–0.390) and drinking alcohol (OR 0.095; CI 0.033–0.157) were significantly associated with a Diameter_{Ade} to Diameter_{Ref} ratio less than 0.505, after adjusting for age, sex, investigated vessel, HbA1c, and hsCRP.

According to available research, this is the first study investigating the effect of adenosine on ER-induced constricted coronary arteries in humans. It was demonstrated that: 1) intracoronary administration of adenosine dilated the ER-induced constricted coronary artery; 2) this effect was not observed in the completely occluded coronary artery in response to ER; 3) the vessel diameter after adenosine administration and its ratio to the reference vessel diameter were significantly smaller in patients with spasm positive results than in those with spasm negative results; and 4) the ratio cut-off value of 0.505 had a high sensitivity (96%) and high specificity (92%) in the prediction of a spasm positive result.

Discussion

Coronary blood flow is regulated via changes in vessel diameter, and vascular resistance of the coronary arteries adjusts to meet the demands for myocardial oxygen [13,
This intrinsic ability of the heart is called autoregulation. It occurs over a wide range of coronary perfusion pressures, primarily mediated by metabolic, myogenic, and endothelial mechanisms [18]. Autoregulatory dilation occurs substantially in small coronary arterioles with diameters less than 150 μm, which are the major site of action of adenosine. Adenosine is a purine nucleoside produced naturally in myocardial cells from the breakdown of adenosine triphosphate during myocardial ischemia [13]. This dilation of small coronary arterioles reduces vascular resistance and decreases the pressure of upstream vessels, followed by vasodilation of larger arterioles and small arteries (140–300 μm diameter), resulting in an increase in coronary blood flow [17, 19]. The question is how the large epicardial coronary artery reacts to an increased blood flow. Shiode et al. [20] demonstrated that adenosine infusion (100 μg/min) via a 3-Fr infusion catheter settled in the middle segment of LAD increased coronary blood flow by +399% in 12 patients with angiographically normal coronary arteries. The proximal segment of LAD, where there was no direct contact with infused adenosine, had a larger diameter by 9.2% in response to blood flow augmentation [20]. This phenomenon is explained by flow-dependent coronary dilation. Lupi et al. [21] further validated epicardial coronary artery vasodilation with intracoronary adenosine infusion in 24 patients with angiographically normal coronary arteries. The increase in coronary diameter strongly correlated with peak coronary blood flow velocity in response to adenosine infusion, suggesting that the phenomenon was caused by a flow-mediated mechanism rather than a direct effect of adenosine [21]. A similar result was obtained with dipyridamole, which dilates epicardial coronary arteries indirectly by inhibiting intramyocardial adenosine re-uptake, provided supportive evidence of a flow-mediated mechanism. Drexler et al. [22] observed flow-dependent epicardial coronary artery dilation using papaverine. However, that response was significantly reduced in the coronary arteries with non-flow-limiting atherosclerosis, suggesting that endothelial function was involved [22]. It has been recognized that flow stimulation induces the endothelium to release endogenous vasodilators including nitric oxide, which subsequently dilates coronary arteries [23, 24]. This mechanism was supported by an observation that such flow-mediated dilation was abolished by removing the endothelium [25]. We found that intracoronary-administered adenosine dilated the epicardial coronary artery that had been vasoconstricted by ER. However, adenosine did not dilate a completely occluded epicardial coronary artery in cases where adenosine could not reach the microvessels that it acted upon to induce flow augmentation. This result supports the theory that the dilation of epicardial coronary artery is
induced by a flow-dependent and endothelial mechanism rather than a direct local effect of adenosine on the epicardial artery. The response was hampered in patients with spasm positive results. Researchers previously reported that healthy endothelial function render the epicardial coronary artery more resilient to vasospasm by producing nitric oxide [26]. This data may explain the hampered response to adenosine which was observed in the patients studied herein. Furthermore, we may posit that patients with poor adenosine response, based on a Diameter$_{Ade}$ to Diameter$_{Ref}$ ratio less than 0.50, are be more prone to vasospasm.

According to the Japanese Circulation Society, a positive finding on coronary angiography is defined as a transient, total or sub-total occlusion (> 90% stenosis) of the coronary artery [15]. However, a sizable number of patients have significant transient occlusion (> 50% stenosis), but do not meet this criterion. In this study, 24.4% of patients in Group 2 (50–90% stenosis) had a spasm positive result with definite ischemic ECG change. In a clinical context, a poor response of spasm-induced epicardial coronary artery to intracoronary adenosine would be a marker for vasospasm severity. It may also be an adjunctive marker to discriminate patients with vasospasm angina from those without vasospasm when ergonovine provocation shows intermediate response.

**Limitations of the study**

Several limitations are acknowledged in the present study. First, coronary blood flow and intracoronary pressure was not measured directly. However, it was reasonable to assume that flow would increase and pressure decrease after adenosine injection, as shown in previous studies. Second, a small number of patients were enrolled from an Asian population at a single center. Therefore, results should be confirmed in larger studies with a more diverse population. Nevertheless, the present findings add to an understanding of coronary dynamics in vasospasm.

**Conclusions**

The present study found that intracoronary administration of adenosine dilated the ergonovine-induced vasoconstricted epicardial coronary artery. However, this was not the case in a completely occluded coronary artery with induced vasospasm, suggesting that
dilation was endothelial-dependent and flow-mediated. Adenosine by itself does not adequately dilate the epicardial arteries. This is of note especially during FFR manipulation and measurement, where nitroglycerin should not be overlooked.

Conflict of interest: None declared

References


Table 1. Demographic and laboratory characteristics.

<table>
<thead>
<tr>
<th></th>
<th>Group 1 (n = 50)</th>
<th>Group 2 (n = 82)</th>
<th>Group 3 (n = 9)</th>
<th>Group 4 (n = 15)</th>
<th>Total (n = 158)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age [years]</td>
<td>56.7 ± 11.7</td>
<td>58.1 ± 10.9</td>
<td>60.0 ± 7.0</td>
<td>54.7 ± 7.6</td>
<td>57.4 ± 10.7</td>
<td>0.569</td>
</tr>
<tr>
<td>Male</td>
<td>23 (44.2%)</td>
<td>52 (63.4%)</td>
<td>7 (77.8%)</td>
<td>14 (93.3%)</td>
<td>96 (60.8%)</td>
<td>0.002</td>
</tr>
<tr>
<td>BMI [kg/m²]</td>
<td>23.6 (21.5–25.5)</td>
<td>24.5 (23.1–26.5)</td>
<td>25.1 (23.1–28.8)</td>
<td>23.4 (22.4–26.0)</td>
<td>24.1 (22.5–26.3)</td>
<td>0.232</td>
</tr>
<tr>
<td>Hypertension</td>
<td>17 (32.7%)</td>
<td>31 (37.8%)</td>
<td>7 (77.8%)</td>
<td>5 (33.3%)</td>
<td>60 (38.0%)</td>
<td>0.090</td>
</tr>
</tbody>
</table>
Table 2. Angiographic characteristics.

<table>
<thead>
<tr>
<th></th>
<th>Group 1 (n = 50)</th>
<th>Group 2 (n = 82)</th>
<th>Group 3 (n = 9)</th>
<th>Group 4 (n = 15)</th>
<th>Total (n = 158)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spasm positive</td>
<td>0 (0.0%)</td>
<td>20 (24.4%)</td>
<td>9 (100%)</td>
<td>15 (100%)</td>
<td>44 (27.8%)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Radial approach</td>
<td>15 (28.8%)</td>
<td>27 (32.9%)</td>
<td>6 (66.7%)</td>
<td>9 (60.0%)</td>
<td>57 (36.1%)</td>
<td>0.031*</td>
</tr>
<tr>
<td>Investigated vessel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LAD and subbranches</td>
<td>15 (28.8%)</td>
<td>35 (42.7%)</td>
<td>1 (11.1%)</td>
<td>9 (60.0%)</td>
<td>60 (38.0%)</td>
<td>0.038</td>
</tr>
<tr>
<td>LCX and subbranches</td>
<td>3 (5.8%)</td>
<td>5 (6.1%)</td>
<td>2 (22.2%)</td>
<td>2 (13.3%)</td>
<td>12 (7.6%)</td>
<td>0.185</td>
</tr>
<tr>
<td>RCA and subbranches</td>
<td>31 (59.6%)</td>
<td>41 (50.0%)</td>
<td>6 (66.7%)</td>
<td>4 (26.7%)</td>
<td>82 (51.9%)</td>
<td>0.121</td>
</tr>
<tr>
<td>---------------------</td>
<td>------------</td>
<td>------------</td>
<td>----------</td>
<td>----------</td>
<td>-----------</td>
<td>-------</td>
</tr>
<tr>
<td>Left main</td>
<td>3 (5.8%)</td>
<td>1 (1.2%)</td>
<td>0 (0.05)</td>
<td>0 (0.0%)</td>
<td>4 (2.5%)</td>
<td>0.536</td>
</tr>
<tr>
<td>Cumulative dose of</td>
<td>90 (90–90)</td>
<td>90 (90–90)</td>
<td>60 (40–90)</td>
<td>30 (10–55)</td>
<td>90 (90–90)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>ergonovine [μg]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DiameterRef [mm]</td>
<td>3.46 ± 0.74</td>
<td>3.49 ± 0.78</td>
<td>3.49 ± 0.89</td>
<td>3.14 ± 0.79</td>
<td>3.45 ± 0.77</td>
<td>0.455</td>
</tr>
<tr>
<td>DiameterER [mm]</td>
<td>2.14 ± 0.56</td>
<td>1.12 ± 0.42</td>
<td>0.29 ± 0.09</td>
<td>0.00 ± 0.00</td>
<td>1.30 ± 0.82</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td>DiameterAde [mm]</td>
<td>2.66 ± 0.66</td>
<td>1.85 ± 0.57</td>
<td>0.73 ± 0.61</td>
<td>0.01 ± 0.04</td>
<td>1.88 ± 0.97</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td>DiameterNa [mm]</td>
<td>3.14 ± 0.76</td>
<td>2.77 ± 0.77</td>
<td>2.84 ± 0.99</td>
<td>2.25 ± 0.67</td>
<td>2.86 ± 0.81</td>
<td>0.001*</td>
</tr>
<tr>
<td>DiameterAde/DiameterRef</td>
<td>0.76 ± 0.09</td>
<td>0.54 ± 0.15</td>
<td>0.22 ± 0.20</td>
<td>0.01 ± 0.02</td>
<td>0.55 ± 0.26</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td>∆Adenosine [mm]</td>
<td>0.51 ± 0.31</td>
<td>0.73 ± 0.39</td>
<td>0.44 ± 0.59</td>
<td>0.01 ± 0.04</td>
<td>0.58 ± 0.42</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td>∆Nitroglycerin [mm]</td>
<td>0.49 ± 0.28</td>
<td>0.93 ± 0.68</td>
<td>2.11 ± 1.25</td>
<td>2.23 ± 0.69</td>
<td>0.97 ± 0.83</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td>∆Sum [mm]</td>
<td>1.00 ± 0.42</td>
<td>1.66 ± 0.70</td>
<td>2.55 ± 0.96</td>
<td>2.25 ± 0.67</td>
<td>1.54 ± 0.78</td>
<td>&lt; 0.001*</td>
</tr>
</tbody>
</table>

Values are mean ± standard deviation or median (interquartile range) or number (percentage). *P value for trend was < 0.05. LCA — left coronary artery; LAD — left anterior descending artery; LCX — left circumflex artery; RCA — right coronary artery.

**Figure 1.** Coronary angiogram of representative cases. **A.** The sequential coronary angiogram of the right coronary artery (RCA) of an 82 year old male. Intracoronary injection of ergonovine provokes spasm in the distal part of the RCA with a diameter of 0.60 mm (85% stenosis, arrow). Intracoronary administration of adenosine dilates it to a diameter of 0.88 mm. A full vasodilation is achieved by nitroglycerine injection and the calculated reference vessel diameter is 3.92 mm resulting in the ratio of DiameterAde to DiameterRef of 0.23; **B.** The sequential coronary angiogram of the RCA of a 59 year old female. The induced spasm is noted in the middle segment of the RCA (91% stenosis, arrow). Intracoronary administration...
of adenosine dilated it to a diameter of 1.84 mm with the ratio of Diameter_{ade} to Diameter_{ref} of 0.67.

**Figure 2.** Mean diameter changes after ergonovine, adenosine, and nitroglycerin administration. A. Mean diameter changes in response to a maximum dose of ergonovine (E_{max}), adenosine, and nitroglycerin according to the result of a spasm test in the overall study population; B. Mean diameter changes in response to the agents, respectively, in Group 2 (induced spasm between 50% and 90%). p values for interaction between the groups with negative and positive results.

**Figure 3.** Box plot for the ratio of Diameter_{Ade} to Diameter_{Ref}. A. Ratio of vessel diameter in response to adenosine injection (Diameter_{Ade}) to diameter of the reference vessel (Diameter_{Ref}) according to the test result in the overall study population; B. Ratio of Diameter_{Ade} to Diameter_{Ref} in Group 2 (induced spasm between 50% and 90%). Values are presented with median (interquartile range). P values are derived by Mann-Whitney U test.

**Figure 4.** Receiver operating characteristics curve for Diameter_{Ade}/Diameter_{Ref} for the result of spasm positive. A ratio of vessel diameter in response to adenosine injection (Diameter_{Ade}) to the diameter of the reference vessel (Diameter_{Ref}) of 0.505 best predicts a positive spasm result with a sensitivity of 96% and specificity of 92%; AUC — area under curve; CI — confidence interval.
B

- **Spasm Positive**
  - $0.64 \pm 0.24$
  - $1.27 \pm 0.34$
  - $2.01 \pm 0.49$
  - $2.78 \pm 0.75$
  - $\Delta 0.70$
  - $\Delta 0.75$
  - $\Delta 1.41$

- **Spasm Negative**
  - $1.34 \pm 0.48$
  - $2.75 \pm 0.85$

$p$ for interaction $= 0.001$
AUC : 0.970 (95% CI: 0.943-0.998)